Figure 5. PGs attenuate the effector functions of NK cells.

PBMCs were pretreated with PGD₂, PGE₂, or a combination of PGD₂ and PGE₂ and incubated with K562 cells. (a,b) Representative FACS profiles showing the effect of PGs on the expression of CD107a on NK cells from the controls (a) or patients with CRS (b). (c) Line graphs showing the percent response of CD107a+ NK cells from the controls (black) or CRS patients (red) with different concentrations of PGs relative to that with vehicle only. (d) Line graphs showing the percent response of intracellular IFN-γ+ NK cells from the controls (black) or CRS patients (red) at varying PG concentrations relative to that with vehicle only. Data are expressed as means ± SDs.